| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-144-12-200606200-00003 |
| P698 | PubMed publication ID | 16785475 |
| P50 | author | Paul Emery | Q19859634 |
| P2093 | author name string | Rene Westhovens | |
| Joel M Kremer | |||
| Larry W Moreland | |||
| Anthony S Russell | |||
| Harry K Genant | |||
| Carlos Abud-Mendoza | |||
| Jean-Claude Becker | |||
| Tracy Li | |||
| Zhiyu Ge | |||
| Jacek Szechinski | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| rheumatoid arthritis | Q187255 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 865-876 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | |
| P478 | volume | 144 |
| Q36702069 | Q36702069 |
| Q37600477 | A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations |
| Q37428436 | A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview |
| Q40372208 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate |
| Q87526876 | A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate |
| Q40592323 | ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis |
| Q37454367 | ANCA-associated vasculitis: from bench research to novel treatments |
| Q34752154 | Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. |
| Q88348165 | Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly |
| Q24240131 | Abatacept for rheumatoid arthritis |
| Q56891106 | Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives |
| Q37672814 | Abatacept for the treatment of rheumatoid arthritis: A review |
| Q34594335 | Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial |
| Q60920131 | Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study |
| Q37307846 | Abatacept in difficult-to-treat juvenile idiopathic arthritis. |
| Q92857546 | Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register |
| Q38032598 | Abatacept in the treatment of lupus |
| Q48738063 | Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial |
| Q36741564 | Abatacept in the treatment of rheumatoid arthritis |
| Q41905727 | Abatacept in the treatment of rheumatoid arthritis |
| Q42950968 | Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial |
| Q52840577 | Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. |
| Q37533319 | Abatacept therapy and safety management |
| Q38006176 | Abatacept therapy and safety management |
| Q34588972 | Abatacept treatment for rheumatoid arthritis |
| Q48252129 | Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. |
| Q35907809 | Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis |
| Q37396468 | Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis |
| Q39368606 | Abatacept: A Review in Rheumatoid Arthritis |
| Q36593078 | Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists |
| Q42663781 | Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis |
| Q34580298 | Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis |
| Q37015967 | Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis |
| Q36967284 | Abatacept: a novel treatment for rheumatoid arthritis |
| Q38116472 | Abatacept: a review of its use in the management of rheumatoid arthritis |
| Q34449851 | Abatacept: the evidence for its place in the treatment of rheumatoid arthritis |
| Q37032656 | Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis |
| Q56889781 | Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis |
| Q39161011 | Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q34782898 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. |
| Q38635415 | An Overview of Organ-Specific Autoimmune Diseases Including Immunotherapy |
| Q40355045 | Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept |
| Q26774874 | Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review |
| Q38857820 | Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review |
| Q90174521 | Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities |
| Q38248092 | Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? |
| Q81651780 | Are withdrawal trials in paediatric rheumatic disease helpful? |
| Q54917641 | Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study. |
| Q44639109 | Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese |
| Q33819684 | Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry |
| Q42249555 | B cells as a target of immune modulation |
| Q37859368 | Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation |
| Q40168997 | Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q26471538 | Biologic interventions for fatigue in rheumatoid arthritis |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q37505012 | Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q35214632 | Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. |
| Q37390458 | Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q33898103 | Biologics and heart failure in rheumatoid arthritis: are we any wiser? |
| Q37765830 | Biologics in children's autoimmune disorders: efficacy and safety |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q34001621 | Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention |
| Q58774487 | Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications |
| Q37333972 | Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion |
| Q37864546 | CD28 co-signaling in the adaptive immune response. |
| Q37676988 | Certolizumab pegol: a new biologic targeting rheumatoid arthritis |
| Q38681685 | Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity |
| Q36796741 | Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). |
| Q38129722 | Changing incidence of orthopedic surgery in rheumatic disease: contributing factors. |
| Q38400396 | Chimeric fusion proteins used for therapy: indications, mechanisms, and safety |
| Q35237588 | Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective |
| Q37404890 | Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors |
| Q34656204 | Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity |
| Q41481648 | Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow |
| Q28066250 | Combination therapy with biologic agents in rheumatic diseases: current and future prospects |
| Q40598586 | Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare |
| Q38210539 | Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis |
| Q27694496 | Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy |
| Q28547851 | Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis |
| Q34124686 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial |
| Q53179392 | Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q50445051 | Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. |
| Q90582460 | Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis |
| Q34110049 | Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate |
| Q46210972 | Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis |
| Q83001629 | Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis |
| Q38170177 | Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis |
| Q38824724 | Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway |
| Q37301126 | Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis |
| Q34593801 | Crohn's disease: beyond antagonists of tumour necrosis factor |
| Q55318901 | Current treatment options for psoriatic arthritis: spotlight on abatacept. |
| Q90102556 | Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders |
| Q37701273 | Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis |
| Q37754640 | Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases |
| Q44550260 | Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice |
| Q58785143 | Distinguishing rheumatoid arthritis from psoriatic arthritis |
| Q36667805 | Drug Insight: abatacept for the treatment of rheumatoid arthritis |
| Q36194054 | Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q91004089 | Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis: Beneficio económico de los ensayos clínicos controlados patrocinados: El gasto evitable en medicamentos para el tratamie |
| Q42245160 | Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? |
| Q28543128 | Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials |
| Q55049410 | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. |
| Q46131525 | Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register |
| Q35318424 | Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Inte |
| Q44525390 | Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study |
| Q58204675 | Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia®as Biological Intensive Treatment for RA (ORBIT) study |
| Q36930704 | Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate |
| Q41449533 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis |
| Q38212142 | Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison |
| Q40447501 | Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. |
| Q61453693 | Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis |
| Q34768442 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). |
| Q37353822 | Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus |
| Q57547667 | Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q35026464 | Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations |
| Q37754665 | Emerging biologics in the treatment of uveitis |
| Q38110963 | Emerging therapies for rheumatoid arthritis |
| Q57956128 | Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis |
| Q35601018 | Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). |
| Q37680729 | Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis |
| Q33392167 | Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data |
| Q38262504 | Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians |
| Q48064243 | Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. |
| Q41922931 | Generalization and extrapolation of treatment effects from clinical studies in rheumatoid arthritis |
| Q47990979 | Genetic deletion of GIT2 prolongs functional recovery and suppresses chondrocyte differentiation in rats with rheumatoid arthritis. |
| Q38073177 | Genistein: the potential for efficacy in rheumatoid arthritis |
| Q34609376 | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial |
| Q34601527 | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study |
| Q43675571 | Guidelines for the drug treatment of rheumatoid arthritis |
| Q57136925 | Gut microbiome in type 1 diabetes: A comprehensive review |
| Q36610390 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study |
| Q37465523 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial |
| Q64999881 | High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis. |
| Q53410422 | How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? |
| Q44083454 | How should impaired morning function in rheumatoid arthritis be treated? |
| Q36080854 | Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice |
| Q36778450 | Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution |
| Q42674160 | Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study |
| Q37883029 | Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. |
| Q36431677 | Immunotherapies: the blockade of inhibitory signals |
| Q27025619 | Immunotherapy in autoimmune type 1 diabetes |
| Q37668179 | Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells |
| Q38129036 | Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. |
| Q36327384 | Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity |
| Q37012723 | Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial |
| Q33725521 | Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept |
| Q37364098 | Improving patient outlook in rheumatoid arthritis: experience with abatacept |
| Q37914956 | Indirect comparison of biological treatments in refractory rheumatoid arthritis. |
| Q37275656 | Induction of remission in rheumatoid arthritis: criteria and opportunities |
| Q37912944 | Infections associated with monoclonal antibody and fusion protein therapy in humans |
| Q33923452 | Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment |
| Q37156636 | Infectious complications associated with monoclonal antibodies and related small molecules |
| Q37427257 | Inflammatory arthritis: an overview for primary care physicians |
| Q34343286 | Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy |
| Q37663873 | Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy |
| Q55018924 | Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. |
| Q42651098 | Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis |
| Q30811550 | Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment |
| Q35208434 | Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial |
| Q42683340 | Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. |
| Q37404886 | Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment |
| Q37511730 | Management of RA medications in pregnant patients |
| Q37510901 | Management of early aggressive rheumatoid arthritis during pregnancy and lactation |
| Q34641300 | Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q34411088 | Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q38054991 | Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis |
| Q37210198 | Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study |
| Q37401259 | Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept |
| Q26829955 | My treatment approach to rheumatoid arthritis |
| Q28073763 | New pharmacological strategies in rheumatic diseases |
| Q36849874 | New therapies for treatment of rheumatoid arthritis |
| Q84598859 | Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? |
| Q37388213 | Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis |
| Q39804633 | Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? |
| Q38076350 | Novel mechanisms of action of the biologicals in rheumatic diseases. |
| Q43759995 | Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples |
| Q38020459 | Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs |
| Q38225611 | Pathophysiology of JIA-associated uveitis |
| Q37391811 | Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis |
| Q37728501 | Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis |
| Q43165952 | Payers Have Biologic Alternative for Patients With Moderate to Severe Rheumatoid Arthritis Who Do Not Respond to Other DMARD Therapies. |
| Q104135137 | Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis |
| Q37781913 | Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets |
| Q45982095 | Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. |
| Q30699616 | Phase IV non-interventional studies in the treatment of rheumatoid arthritis with biologicals in Germany : real-life clinical practice data |
| Q36981540 | Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis |
| Q38186577 | Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review |
| Q37397646 | Randomized controlled trial design in rheumatoid arthritis: the past decade |
| Q34153073 | Rationale of using different biological therapies in rheumatoid arthritis |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q58087985 | Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again |
| Q36757047 | Recent developments in the immunobiology of rheumatoid arthritis |
| Q35919783 | Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway |
| Q38085279 | Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab |
| Q38149252 | Rheumatoid arthritis and cardiovascular disease |
| Q38357554 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges |
| Q37739480 | Rheumatoid arthritis therapy: advances from bench to bedside |
| Q90665225 | Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study |
| Q33809045 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics |
| Q33315300 | Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials |
| Q26991673 | Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies |
| Q41176187 | Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides |
| Q64993375 | Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. |
| Q44464975 | Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study |
| Q38665700 | Safety profile of biological therapies for treating rheumatoid arthritis |
| Q38374478 | Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. |
| Q40374825 | Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis |
| Q37766214 | Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 compariso |
| Q48933199 | Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japa |
| Q37954363 | Small molecular therapies for rheumatoid arthritis: where do we stand? |
| Q45230346 | Sonographic measurements of low-echoic synovial area in the dorsal aspect of metatarsophalangeal joints in healthy subjects |
| Q35953458 | Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study |
| Q27692117 | Subcutaneous abatacept for the treatment of rheumatoid arthritis |
| Q35590496 | Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. |
| Q64071210 | Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with |
| Q39904758 | Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. |
| Q34523450 | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 |
| Q38693137 | T Helper 17 Cells in Primary Sjögren's Syndrome |
| Q91755050 | T follicular helper cells and T follicular regulatory cells in rheumatic diseases |
| Q36972497 | T-cell co-stimulatory pathways in autoimmunity |
| Q50082712 | Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis. |
| Q39344907 | Targeting the programmed cell death-1 pathway in rheumatoid arthritis. |
| Q38328280 | Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. |
| Q37374964 | The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial |
| Q43913784 | The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation |
| Q30914777 | The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q37044693 | The burden of rheumatoid arthritis and access to treatment: a medical overview |
| Q35048356 | The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor |
| Q43038371 | The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial |
| Q36059373 | The efficacy and safety of abatacept in rheumatoid arthritis. |
| Q37760938 | The efficacy and safety of golimumab in the treatment of arthritis |
| Q37800488 | The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials |
| Q48029200 | The pathogenesis of rheumatoid arthritis: new insights from old clinical data? |
| Q34364057 | The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials |
| Q54998113 | The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. |
| Q92627208 | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
| Q33962865 | Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. |
| Q37226317 | Tocilizumab: the first interleukin-6-receptor inhibitor |
| Q58204744 | Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study |
| Q36972500 | Translating co-stimulation blockade into clinical practice. |
| Q41450339 | Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs |
| Q38679486 | Treatment of adult-onset still's disease: up to date. |
| Q36663141 | Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly |
| Q35927877 | Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study |
| Q37158791 | Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review |
| Q47132835 | Treatment with Biologicals in Rheumatoid Arthritis: An Overview. |
| Q37378378 | Trials in rheumatoid arthritis: choosing the right outcome measure when minimal disease is achievable |
| Q38871098 | Unintended Immunological Consequences of Biologic Therapy. |
| Q37851001 | Unresolved issues in biologic therapy for rheumatoid arthritis |
| Q36869567 | Update on abatacept: a selective costimulation modulator for rheumatoid arthritis |
| Q38125240 | Update on the use of abatacept for the treatment of rheumatoid arthritis. |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q36626213 | Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis |
| Q30863740 | Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study |
| Q35869036 | Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects |
| Q47967125 | Validation and relevance of Rheumatoid Arthritis Pain Scale (RAPS) in Indian (Asian) patients suffering from rheumatoid arthritis |
| Q63101754 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e |
| Q37842638 | What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? |
| Q39237760 | What drives the comparative effectiveness of biologics vs. methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors |
| Q37831972 | When to initiate and discontinue biologic treatments for rheumatoid arthritis? |
| Q83398658 | [A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] |
| Q83299536 | [Combination therapy using methotrexate with DMARDs or biologics--current status] |
| Q84726054 | [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis] |
| Q52885796 | [Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy]. |
| Q81814153 | [Recommedations for the use of abatacept in patients with rheumatoid arthritis] |
| Q52895477 | [Therapeutic strategies in rheumatoid arthritis]. |
Search more.